Could a tiny dose of this drug help men with prostate cancer avoid surgery?
NCT ID NCT04530552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might offer a way to delay or avoid surgery or radiation in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide (a drug that blocks testosterone's effect on prostate cancer)
What this could lead to
If successful, this could support using low-dose apalutamide to help men with early prostate cancer delay surgery or radiation.
What could go wrong
This is a small, early-phase study (34 participants) testing only a short-term effect on PSA, not long-term outcomes. The low dose may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
George Washington University Medical Center
Washington D.C., District of Columbia, 20037, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Arizona Cancer Center - Prevention Research Clinic
Tucson, Arizona, 85719, United States